Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.59 |
| ▸ | PGK1 | P00558 | 2/20 | 0.57 |
| ▸ | PGK2 | P07205 | 2/20 | 0.57 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.52 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4798221 | 0.93 | ADORA3 (0.58) | ADORA3PGK1PGK2SLC29A1ADORA1 | |
| SCHEMBL4798374 | 0.89 | ADORA3 (0.65) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL4804718 | 0.87 | PGK1 (0.51) | ADORA3PGK1PGK2ADORA1ADORA2A | |
| SCHEMBL4801695 | 0.86 | ADORA3 (0.64) | ADORA3PGK1PGK2SLC29A1ADORA1 | |
| SCHEMBL4804672 | 0.85 | ADORA3 (0.62) | ADORA3SLC29A1ADORA1ADORA2AADORA2B | |
| SCHEMBL4804739 | 0.84 | ADORA3 (0.55) | ADORA3SLC29A1ADORA1ADORA2AADORA2B | |
| SCHEMBL4807108 | 0.84 | ADORA3 (0.68) | ADORA3SLC29A1ADORA1ADORA2AADORA2B | |
| SCHEMBL5129366 | 0.84 | ADORA3 (0.68) | ADORA3SLC29A1ADORA1ADORA2AADORA2B | |
| SCHEMBL5129355 | 0.84 | ADORA3 (0.68) | ADORA3SLC29A1ADORA1ADORA2AADORA2B | |
| SCHEMBL4806841 | 0.84 | CYP1A2 (0.63) | ADORA3SLC29A1ADORA1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7381714-B2 | A1 adenosine receptor agonists | CV THERAPEUTICS, INC. (US) | 2008-06-03 | — | — | US | disclosed |
| EP-1883646-A1 | A1 ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2008-02-06 | — | — | EP | disclosed |
| US-20060276428-A1 | A1 adenosine receptor agonists | CV THERAPEUTICS, INC. | 2006-12-07 | — | — | US | disclosed |
| WO-2006125190-A1 | A1 ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276428-A1 | A1 adenosine receptor agonists | ADORA1, ADORA2A, ADORA3 | ADORA3 3/4885PGK1 1806/4885PGK2 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.